CI
The Cigna (CI)
NYSE
$281.93-$0.15 (-0.05%)
Price as of Jun 23, 2026 12:46 PM EDT
  • $74.6B
    Market Cap
  • -9.04%
    1-Year Change
  • Healthcare Plans
    Industry

Key Performance

More
  • Earnings Score: 28
  • Momentum Score: 30
  • True Yield: 46
  • Financial Health Score: 76
TradeSmith Loading

Latest Research & News

GILC Convenes World Leaders on Social Connection and Division During Global Loneliness Awareness Week

The Global Initiative on Loneliness and Connection (GILC) is hosting the Global Connection Forum on June 17, 2026, to address social disconnection as a major public health and economic challenge. The forum will bring together leaders from public health, policy, and philanthropy to explore how social connection can repair polarization and division. Research shows chronic disconnection increases illness risk by 26-28% and costs employers $159 billion annually in lost productivity.

06/10/2026, 1:43 PMGlobeNewswire

Cigna Raises Outlook, Flags Individual Exchange Exit And Strategic Review Of eviCore

Cigna reported Q1 2026 adjusted earnings of $7.79 per share, beating consensus of $7.61, with sales rising 5% to $68.52 billion. The company raised its full-year adjusted EPS outlook to at least $30.35. However, Cigna announced plans to exit the individual exchange business by year-end and initiated a strategic review of eviCore. CEO David Cordani will transition to Executive Chair, with Brian Ivanko becoming CEO in July 2026.

04/30/2026, 2:58 PMBenzinga

The Cigna Group Declares Quarterly Dividend

The Cigna Group's Board of Directors declared a quarterly cash dividend of $1.56 per share, payable on June 18, 2026, to shareholders of record as of June 4, 2026.

04/22/2026, 4:30 PMBenzinga

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

03/20/2026, 12:07 PMThe Motley Fool

Ushur Launches Voice-Guided Experience for Synchronized Voice and Visual Customer Interactions in Regulated Industries

Ushur announced Voice-Guided Experience, a new capability that enables organizations in regulated industries to guide customers through complex workflows using synchronized voice and mobile interactions. The AI-powered feature keeps voice conversations active while opening a synchronized mobile experience, allowing customers to speak or tap without switching channels. The platform supports 74 languages, maintains enterprise-grade compliance (HITRUST r2, SOC 2, HIPAA), and is designed to improve completion rates and reduce operational burden for healthcare, insurance, and financial services organizations.

03/19/2026, 12:00 PMGlobeNewswire

Dental Insurance Global Market Forecast 2026-2032: Plan Types, Customer Types, Distribution Channels, Coverage Levels, Regions, Technologies

The global dental insurance market is projected to grow from USD 118.77 billion in 2026 to USD 198.31 billion by 2032, with a CAGR of 8.72%. Growth is driven by digital transformation, evolving care models, and regulatory shifts. Key trends include provider consolidation, value-based care models, and increased investment in analytics and digital-first distribution channels.

03/16/2026, 12:00 PMGlobeNewswire

Cummins Revenue Holds Up as Charges Weigh on Near-Term Earnings Clarity

In recent earnings releases, KKR reported strong revenue of $5.74B (beating $2.11B expectations) but missed on EPS at $1.12 vs $1.14 expected. Cummins exceeded revenue expectations at $8.5B but fell short on EPS at $4.27 vs $5.01 expected due to Electrolyzer business charges. The Cigna Group outperformed on both metrics with $72.47B revenue and $8.08 EPS, demonstrating strong operational discipline.

02/05/2026, 1:19 PMInvesting

FTC Settlement With Cigna's Pharmacy Benefit Manager Promises Cheaper Insulin, Boosts Dividend On Strong Quarterly Earnings

The FTC finalized a settlement with Cigna's Express Scripts pharmacy benefit manager to reduce anticompetitive practices and lower insulin costs by up to $7 billion over the next decade. Cigna reported strong Q4 2025 earnings, beating revenue and EPS estimates, and increased its quarterly dividend to $1.56 per share. The stock rose 3.53% following the announcement.

02/05/2026, 12:49 PMBenzinga

Cummins Revenue Holds Up as Charges Weigh on Near-Term Earnings Clarity

In Q4 2025 earnings, KKR exceeded revenue expectations at $5.74B but missed on EPS. Cummins beat revenue at $8.5B but fell short on EPS due to Electrolyzer business charges, though it projects 3-8% revenue growth for 2026. Cigna Group outperformed on both revenue ($72.47B) and EPS ($8.08), reflecting strong operational performance.

02/05/2026, 12:17 PMInvesting

Boom! FTC Squeezes Concessions from Cigna’s Express Scripts

The FTC has secured a landmark settlement with Cigna's Express Scripts requiring elimination of spread pricing, decoupling rebates from drug list prices, relocating its GPO from Switzerland to the U.S., and adopting a cost-plus reimbursement model for independent pharmacies starting in 2027. The NCPA views this as a major victory against anticompetitive PBM practices that have artificially inflated drug prices and harmed independent pharmacies.

02/04/2026, 12:55 PMGlobeNewswire

FTC Delays Drug Middlemen Case While Talks Move Forward

The FTC has paused its administrative case against major pharmacy benefit managers (PBMs) including Cigna, CVS Health, and UnitedHealth Group, suggesting settlement negotiations may be underway. The 14-day suspension delays the evidentiary hearing to July 1. The case, filed in September 2024, accuses PBMs of unfair practices that inflated insulin prices. Recent investigations and political pressure from the Trump administration have intensified scrutiny on PBM practices, particularly regarding markups on specialty drugs and alleged use of shell companies to obscure profits.

01/23/2026, 1:31 PMBenzinga

UnitedHealth CEO Says Hospitals, Drug Prices Drive US Health Care Costs, Pledges ACA Rebates

UnitedHealth Group CEO Stephen Hemsley testified before House panels that rising hospital prices, consolidation, and prescription drug costs—not insurers—are the primary drivers of U.S. health care spending. He pledged to voluntarily eliminate and rebate profits on ACA exchange coverage this year and urged policy reforms including site-neutral payments and patent reform. UnitedHealth also announced a pilot program to accelerate Medicare Advantage payments for rural hospitals.

01/22/2026, 6:58 AMBenzinga

Are CVS, UnitedHealth, Cigna Hiding Billions In PBM Rebates? New Report Claims They Are

A new report from Hunterbrook Media alleges that CVS Health, UnitedHealth Group, and Cigna are using shell subsidiary companies called GPOs (Group Purchasing Organizations) to hide billions of dollars in drug rebates that should be passed to patients. The report claims these companies collect massive fees through their GPOs while telling customers they've passed on 100% of rebates, effectively siphoning off drug discounts meant for patients. Hunterbrook visited the GPO headquarters in Ireland, Switzerland, and Minnesota, finding mostly empty offices despite handling tens of billions in revenue.

01/06/2026, 6:35 PMBenzinga

Cigna Offers Cleaner Growth Than Other Health Insurers, Says Analyst

BofA Securities highlighted Cigna's strong potential in commercial health insurance, noting its pharmacy benefit management platform and ability to deliver 10-15% annual EPS growth, while also discussing challenges and opportunities in the healthcare insurance market.

12/17/2025, 1:55 PMBenzinga

Meet the 2.5% Yield Dividend Stock That Could Soar in 2026

UnitedHealth Group's stock has dropped 35% in 2025 due to misjudged medical service costs, but the company plans to improve profit margins in 2026-2027 by adjusting Medicare Advantage bids and negotiating better rates.

12/09/2025, 3:05 PMThe Motley Fool

Peers

Statistics

More
Day Range
$279.39
$284.25
$282.08
1-Year Range
$244.41
$334.39
$282.08
Latest Close$282.08
Change
+$2.81 (+1.00%)
Volume1,498,646
Market Cap$74.6B
Shares Outstanding264.5M
P/E (TTM)12.11
Diluted EPS (TTM)$23.29
Enterprise Value$98.5B

Information as of 06/22/2026

Company Profile

$74.6B
Market Cap
$6.2B
Net Income
Sector: Healthcare
Industry: Healthcare Plans
900 Cottage Grove Road, Bloomfield, CT, United States, 06002
860 226 6000

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

Key Executives

  • David Michael Cordani
  • Brian C. Evanko
  • Nicole Susan Jones
  • Ann Dennison
  • Durga Prasad Koka

Current Ownership Distribution

  • Mutual Funds9.7B (68.10%)
  • Institutions4.5B (31.90%)
  • Insiders845,889 (0.006%)
  • Other0 (0.00%)